Latest News

1403, 2017

ATLAS Molecular Pharma has been awarded with one of the prestigious NEOTEC grants (2016 call)

ATLAS Molecular Pharma succeeded with the competitive NEOTEC call (CDTI), obtaining a grant for a total amount of 213.000 EUR during the period 2017-2018. The NEOTEC Program aims to support the creation and consolidation of [...]

603, 2017

A possible pharmacological chaperone for congenital erythropoietic porphyria

The Chassys platform has been successfully applied for the identification of a series of putative pharmacological chaperones for the treatment of congenital erythropoietic porphyria. One of them is currently being validated, with most promising results. [...]

Go to Top